UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Cardiovascular complications of conventional and targeted adjuvant breast cancer therapy

Annals of oncology, 2011-06, Vol.22 (6), p.1250-1258

2011

Volltextzugriff (PDF)

Is cardiotoxicity being adequately assessed in current trials of cytotoxic and targeted agents in breast cancer?

Annals of oncology, 2011-05, Vol.22 (5), p.1011-1018

2011

Volltextzugriff (PDF)

Cancer drugs and the heart: importance and management

European heart journal, 2013-04, Vol.34 (15), p.1102-1111

2013

Volltextzugriff (PDF)

Electrocardiograms (ECGs) in phase I anticancer drug development: the MD Anderson Cancer Center experience with 8518 ECGs

Annals of oncology, 2012-11, Vol.23 (11), p.2960-2963

2012

Volltextzugriff (PDF)

Pertuzumab, trastuzumab, and standard anthracycline- and taxane-based chemotherapy for the neoadjuvant treatment of patients with HER2-positive localized breast cancer (BERENICE): a phase II, open-label, multicenter, multinational cardiac safety study

Annals of oncology, 2018-03, Vol.29 (3), p.646-653

2018

Volltextzugriff (PDF)

Cardioprotection with dexrazoxane for doxorubicin-containing therapy in advanced breast cancer

Journal of clinical oncology, 1997-04, Vol.15 (4), p.1318-1332

1997

Volltextzugriff (PDF)

Delayed administration of dexrazoxane provides cardioprotection for patients with advanced breast cancer treated with doxorubicin-containing therapy

Journal of clinical oncology, 1997-04, Vol.15 (4), p.1333-1340

1997

Volltextzugriff (PDF)

Cardiotoxicity in patients receiving Trastuzumab (Herceptin) : Primary toxicity, synergistic or sequential stress, or surveillance artifact?

Seminars in oncology, 1999-08, Vol.26 (4), p.96-101

1999

Volltextzugriff (PDF)

Cardiac safety of dual anti-HER2 blockade with pertuzumab plus trastuzumab in early HER2-positive breast cancer in the APHINITY trial

ESMO open, 2023-02, Vol.8 (1), p.100772, Article 100772

2023

Volltextzugriff (PDF)

Idarubicin cardiotoxicity: a retrospective study in acute myeloid leukemia and myelodysplasia

Journal of clinical oncology, 1995-11, Vol.13 (11), p.2827-2834

1995

Volltextzugriff (PDF)

Decreased cardiac toxicity of doxorubicin administered by continuous intravenous infusion in combination chemotherapy for metastatic breast carcinoma

Cancer, 1989-01, Vol.63 (1), p.37-45

1989

Volltextzugriff (PDF)

Expert consensus for multimodality imaging evaluation of adult patients during and after cancer therapy: a report from the American Society of Echocardiography and the European Association of Cardiovascular Imaging

European heart journal cardiovascular imaging, 2014-10, Vol.15 (10), p.1063-1093

2014

Volltextzugriff (PDF)

Characteristics of cardiac arrest in cancer patients as a predictor of survival after cardiopulmonary resuscitation

Cancer, 2001-10, Vol.92 (7), p.1905-1912

2001

Volltextzugriff (PDF)

Advance directives in the intensive care unit of a tertiary cancer center

Cancer, 1995-10, Vol.76 (7), p.1268-1274

1995

Volltextzugriff (PDF)

A comparison of cardiac biopsy grades and ejection fraction estimations in patients receiving Adriamycin

Journal of clinical oncology, 1984-02, Vol.2 (2), p.112-117

1984

Volltextzugriff (PDF)

Type II chemotherapy-related cardiac dysfunction: time to recognize a new entity

Journal of clinical oncology, 2005-05, Vol.23 (13), p.2900-2902

2005

Volltextzugriff (PDF)

Returns to physician human capital: Evidence from patients randomized to physician teams

Journal of health economics, 2010-12, Vol.29 (6), p.866-882

2010

Volltextzugriff (PDF)

A comparative study of doxorubicin and epirubicin in patients with metastatic breast cancer

American journal of clinical oncology, 1989-02, Vol.12 (1), p.57-62

1989

Volltextzugriff (PDF)

Congestive heart failure in patients treated with doxorubicin: A retrospective analysis of three trials

Cancer, 2003-06, Vol.97 (11), p.2869-2879

2003

Volltextzugriff (PDF)

Cardiac transplantation and aspergillosis

Circulation (New York, N.Y.), 1994-09, Vol.90 (3), p.1552-1556

1994

Volltextzugriff (PDF)

Reversibility of Trastuzumab-Related Cardiotoxicity: New Insights Based on Clinical Course and Response to Medical Treatment

Journal of clinical oncology, 2005-11, Vol.23 (31), p.7820-7826

2005

Volltextzugriff (PDF)

Predicting Loss of Pulmonary Function After Pulmonary Resection for Bronchogenic Carcinoma

Chest, 1980-03, Vol.77 (3), p.337-342

1980

Volltextzugriff (PDF)

The definition of medical futility: Are we trying to define the wrong term?

Heart & lung, 2001-01, Vol.30 (1), p.3-4

Ewer, Michael S.

2001

Volltextzugriff (PDF)

Perspective on the Cardiotoxicity of Third-Generation Targeted EGFRs in the Treatment of NSCLC

JTO clinical and research reports, 2021-10, Vol.2 (10), p.100233-100233, Article 100233

2021

Volltextzugriff (PDF)

1 – 25 von 435

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(369)
Mit Volltextzugriff
(343)

Publikationsform

2 weitere anzeigen...

Weniger anzeigen...

Sprache

Englisch
(433)
Deutsch
(2)

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Cardiovascular complications of conventional and targeted adjuvant breast cancer therapy

Is cardiotoxicity being adequately assessed in current trials of cytotoxic and targeted agents in breast cancer?

Cancer drugs and the heart: importance and management

Electrocardiograms (ECGs) in phase I anticancer drug development: the MD Anderson Cancer Center experience with 8518 ECGs

Pertuzumab, trastuzumab, and standard anthracycline- and taxane-based chemotherapy for the neoadjuvant treatment of patients with HER2-positive localized breast cancer (BERENICE): a phase II, open-label, multicenter, multinational cardiac safety study

Cardioprotection with dexrazoxane for doxorubicin-containing therapy in advanced breast cancer

Delayed administration of dexrazoxane provides cardioprotection for patients with advanced breast cancer treated with doxorubicin-containing therapy

Cardiotoxicity in patients receiving Trastuzumab (Herceptin) : Primary toxicity, synergistic or sequential stress, or surveillance artifact?

Cardiac safety of dual anti-HER2 blockade with pertuzumab plus trastuzumab in early HER2-positive breast cancer in the APHINITY trial

Idarubicin cardiotoxicity: a retrospective study in acute myeloid leukemia and myelodysplasia

Decreased cardiac toxicity of doxorubicin administered by continuous intravenous infusion in combination chemotherapy for metastatic breast carcinoma

Expert consensus for multimodality imaging evaluation of adult patients during and after cancer therapy: a report from the American Society of Echocardiography and the European Association of Cardiovascular Imaging

Characteristics of cardiac arrest in cancer patients as a predictor of survival after cardiopulmonary resuscitation

Advance directives in the intensive care unit of a tertiary cancer center

A comparison of cardiac biopsy grades and ejection fraction estimations in patients receiving Adriamycin

Type II chemotherapy-related cardiac dysfunction: time to recognize a new entity

Returns to physician human capital: Evidence from patients randomized to physician teams

A comparative study of doxorubicin and epirubicin in patients with metastatic breast cancer

Congestive heart failure in patients treated with doxorubicin: A retrospective analysis of three trials

Cardiac transplantation and aspergillosis

Reversibility of Trastuzumab-Related Cardiotoxicity: New Insights Based on Clinical Course and Response to Medical Treatment

Predicting Loss of Pulmonary Function After Pulmonary Resection for Bronchogenic Carcinoma

The definition of medical futility: Are we trying to define the wrong term?

Significantly Higher Pathologic Complete Remission Rate After Neoadjuvant Therapy With Trastuzumab, Paclitaxel, and Epirubicin Chemotherapy: Results of a Randomized Trial in Human Epidermal Growth Factor Receptor 2–Positive Operable Breast Cancer

Perspective on the Cardiotoxicity of Third-Generation Targeted EGFRs in the Treatment of NSCLC

Suchergebnisse filtern